Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative therapies to treat a variety of diseases, including cancer and autoimmune disorders. The company specializes in applying its proprietary drug delivery technology to enhance the efficacy and safety of existing therapies, as well as creating new treatments from the ground up. Nektar collaborates with other pharmaceutical organizations to advance its research pipeline and aims to address unmet medical needs by delivering transformative medicines that improve patients' lives. Read More
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a novel, first-in-class regulatory T cell stimulator for the treatment of, inter alia, alopecia areata.
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire founder, Dr. Patrick Soon-Shiong, the company has rapidly evolved into a commercial-stage powerhouse in the immunotherapy landscape. ImmunityBio is currently in focus due to [...]
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.
Nektar Therapeutics (NKTR) Q3 2025 results beat analyst estimates for both revenue and earnings per share, sending the stock higher in after-hours trading.
